Lymphoma, T-Cell, Peripheral: Clinical Trials

362 trials for Lymphoma, T-Cell, Peripheral, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

139 completed, 65 unknown, 56 recruiting, 46 terminated. 188 Phase 2, 148 Phase 1, 25 Phase 3, 17 Not applicable, 8 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2188Completed 74, Unknown 35, Recruiting 28, Terminated 21, Not yet recruiting 15, Active not recruiting 7, Withdrawn 7, Suspended 1
Phase 1148Completed 63, Terminated 30, Recruiting 20, Unknown 14, Not yet recruiting 10, Active not recruiting 6, Suspended 4, Withdrawn 1
Phase 325Recruiting 8, Completed 5, Unknown 4, Withdrawn 3, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Terminated 1
Not applicable17Unknown 5, Completed 4, Recruiting 3, Terminated 3, Not yet recruiting 1, Withdrawn 1
Early Phase 18Unknown 4, Recruiting 2, Completed 1, Terminated 1
Phase 45Unknown 4, Completed 1

Follow Lymphoma, T-Cell, Peripheral: new trials by email Literature Review of Lymphoma, T-Cell, Peripheral trials Research Report on Lymphoma, T-Cell, Peripheral

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma
Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Phase 1Not yet recruitingThe Methodist Hospital Research Institute212027-01-152026-11-12
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
GNTbm-38 - Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1Not yet recruitingGreat Novel Therapeutics Biotech & Medicals Corporation702026-12-012026-09-25
Allogeneic Cell Therapy in Refractory T-Cell Lymphoma
Baseline FDG-PET/CT, First-line chemotherapy, Interim FDG-PET/CT after two cycles of first-line chemotherapy - Lymphoma, T Cell, Peripheral
Phase 2Not yet recruitingUniversity Medical Center Goettingen702026-11-012026-11-05
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
Phase 1 / Phase 2Not yet recruitingMedsyn Biopharma, LLC752026-11-012026-10-27
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
KK2223 - T-cell NHL (PTCL or CTCL)
Phase 1RecruitingKyowa Kirin, Inc.722026-09-022026-09-30
The Efficacy of CAPCT in Patients With PTCL
Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma
Phase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University582026-08-012026-08-05
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Non-Hodgkin Lymphoma, T-Cell Lymphoma
RecruitingNatera, Inc.2002026-07-272026-08-06
New Genotype-guided Treatment in Newly Diagnosed PTCL
Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL)
Phase 1 / Phase 2Not yet recruitingRuijin Hospital1082026-07-012026-07-16
A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.
PTCL, T Cell Lymphoma
Not yet recruitingRuijin Hospital10002026-06-012026-06-18
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Adebrelimab & SHR2554 - Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University402026-05-292026-05-29
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Anti-TRBC1 CAR-T cells - Refractory/Recurrent Peripheral T-cell Lymphoma
Phase 1RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine452026-04-012026-03-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Aclarubicin, Cyclophosphamide, Vincristine - Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Phase 2Not yet recruitingShanghai Jiao Tong University School of Medicine362026-03-302026-04-17
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
PET-CTandct- DNAdetection, golidocitinib, Placebo - Maintenance Treatment of Peripheral T-cell Lymphoma
Phase 3RecruitingFudan University1362026-03-272026-03-31
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma
Phase 1RecruitingNational Cancer Institute (NCI)202026-03-262026-11-09
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Phase 1 / Phase 2RecruitingBeijing Biotech962026-03-022026-04-13
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Brentuximab Vedotin Plus CHP - CD30-Positive Peripheral T-Cell Lymphoma
RecruitingGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea1002026-02-152026-06-03
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
golidocitinib, Placebo - Peripheral T Cell Lymphoma
Phase 3RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine682026-02-152026-02-24
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease
Phase 2RecruitingOhio State University Comprehensive Cancer Center442026-02-122026-10-27
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
BR101801 - Peripheral T Cell Lymphoma
Phase 2Not yet recruitingBoryung Pharmaceutical Co., Ltd442026-02-012026-01-28
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Cidabenamine, Azacitidine - Peripheral T Cell Lymphoma
Phase 2 / Phase 3RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine402026-02-012026-02-05

Showing 20 of 362. Sign in to see all of them.

Narrower conditions

Lymphoma, T-Cell, Cutaneous (85)  ·  Lymphoma, Large B-Cell, Diffuse (82)  ·  Lymphoma, Large-Cell, Anaplastic (81)  ·  Lymphoma, Non-Hodgkin (81)  ·  Immunoblastic Lymphadenopathy (70)  ·  Lymphoma, Extranodal NK-T-Cell (66)  ·  Hodgkin Disease (64)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (63)  ·  Lymphoma, Follicular (61)  ·  Lymphoma, Mantle-Cell (58)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (58)  ·  Recurrence (58)  ·  Mycosis Fungoides (57)  ·  Lymphoma, B-Cell, Marginal Zone (55)

Broader conditions

Hemic and Lymphatic Diseases (362)  ·  Immunoproliferative Disorders (362)  ·  Lymphatic Diseases (361)  ·  Neoplasms by Histologic Type (361)  ·  Immune System Diseases (360)  ·  Lymphoproliferative Disorders (357)  ·  Neoplasms (356)  ·  Lymphoma, T-Cell (323)  ·  Lymphoma (314)  ·  Lymphoma, Non-Hodgkin (281)  ·  Pathologic Processes (110)  ·  Pathological Conditions, Signs and Symptoms (110)  ·  Disease Attributes (109)  ·  Hematologic Diseases (108)  ·  Leukemia, Lymphoid (98)

Interventions

Cyclophosphamide (47)  ·  Prednisone (33)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (31)  ·  Vincristine (29)  ·  Doxorubicin (28)  ·  Etoposide (23)  ·  romidepsin (20)  ·  Gemcitabine (18)  ·  Lenalidomide (16)  ·  10-propargyl-10-deazaaminopterin (15)  ·  Azacitidine (15)  ·  Whole-Body Irradiation (15)  ·  fludarabine phosphate (15)  ·  Brentuximab Vedotin (14)  ·  Peripheral Blood Stem Cell Transplantation (14)

Sponsors

National Cancer Institute (NCI) (16)  ·  Fred Hutchinson Cancer Center (14)  ·  Ruijin Hospital (14)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (9)  ·  Sun Yat-sen University (8)  ·  Acrotech Biopharma Inc. (7)  ·  Fudan University (6)  ·  Institute of Hematology & Blood Diseases Hospital, China (5)  ·  M.D. Anderson Cancer Center (5)  ·  Peking Union Medical College Hospital (5)  ·  Case Comprehensive Cancer Center (4)  ·  Celgene (4)  ·  Dizal Pharmaceuticals (4)  ·  Kyowa Kirin Co., Ltd. (4)  ·  The Lymphoma Academic Research Organisation (4)

Countries

United States (164)  ·  China (106)  ·  Italy (34)  ·  France (28)  ·  Spain (25)  ·  South Korea (22)  ·  Canada (20)  ·  United Kingdom (20)  ·  Japan (18)  ·  Germany (17)  ·  Australia (16)  ·  Belgium (11)  ·  Denmark (10)  ·  Poland (9)  ·  Taiwan (9)

Top investigators

David Maloney (4)  ·  Ajay Gopal (3)  ·  Brenda Sandmaier (3)  ·  Ryan Wilcox, MD, PhD (3)  ·  Weili Zhao (3)  ·  Abhinav Deol, M.D. (2)  ·  Andrei Shustov, MD (2)  ·  Ann Woolfrey (2)  ·  Barbara Pro, MD (2)  ·  Beata Holkova, MD (2)  ·  Daobin Zhou, MD (2)  ·  Dehui Zou, Dr. (2)

Results publications

PMID 32499241, PMID 25113753, PMID 31029646, PMID 33051668, PMID 1244564, PMID 16731764, PMID 18042692, PMID 18626005, PMID 18698002, PMID 19597183, PMID 19826128, PMID 19880495, PMID 19900571, PMID 20671118, PMID 21270441, PMID 21355097, PMID 21504290, PMID 21576639, PMID 22259028, PMID 22271479, PMID 23023715, PMID 23049383, PMID 23278639, PMID 23393050, PMID 23649469, PMID 23674495, PMID 23716537, PMID 23752175, PMID 23818604, PMID 24142051, PMID 24359243, PMID 24456586, PMID 24474568, PMID 24652992, PMID 24827808, PMID 25279222, PMID 25404094, PMID 25482745, PMID 25605368, PMID 25605745, PMID 25879747, PMID 25891346, PMID 26202875, PMID 26213141, PMID 26222726, PMID 26353084, PMID 26377597, PMID 26424652, PMID 26542718, PMID 26659919

NIH funding

P30CA015704 (12), 2023 (4), P01CA018029 (4), 2019 (2), P01CA078902 (2), P30CA016672 (2), P30CA036727 (2), P30CA043703 (2), P30CA072720 (2), U01CA097452 (2), U10CA021115 (2), 2008 (1), 2017 (1), 2025 (1), K12CA167540 (1)